By Groov Wellness Editorial Team · Updated 2026-08-25
Semaglutide and Tirzepatide, both offered at Groov Wellness as self-injectable therapies, are FDA-approved medications used in physician-guided weight loss programs. In a major clinical trial, adults taking semaglutide 2.4 mg alongside lifestyle intervention lost an average of about 15% of their body weight over 68 weeks, while Tirzepatide’s dual GIP/GLP-1 action has produced average weight loss of 20% or more for some patients in major trials. These are group averages, not guarantees — individual results vary. Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon, remains investigational and is not yet FDA-approved. Groov Wellness providers evaluate each San Antonio patient individually, tailoring medication choice, dosing, and support to their metabolic goals and health history.
Key Takeaways
Semaglutide is an FDA-approved GLP-1 medication; in a major clinical trial, adults lost an average of about 15% of their body weight over 68 weeks alongside lifestyle changes.
Tirzepatide activates both GIP and GLP-1 receptors and has produced average weight loss of 20% or more in major trials for some patients — though individual results vary.
Choosing between Semaglutide and Tirzepatide depends on medical history, prior response, tolerability, and personal goals, best determined through a clinical evaluation.
Retatrutide is an investigational triple agonist still in clinical trials and is not currently FDA-approved or available as a standard treatment, at Groov Wellness or elsewhere.
Groov Wellness pairs medication with personalized dosing, nutrition guidance, and ongoing support to help patients build sustainable results.
Semaglutide is an FDA-approved GLP-1 medication; in a major clinical trial, adults lost an average of about 15% of their body weight over 68 weeks alongside lifestyle changes.
Tirzepatide activates both GIP and GLP-1 receptors and has produced average weight loss of 20% or more in major trials for some patients — though individual results vary.
Choosing between Semaglutide and Tirzepatide depends on medical history, prior response, tolerability, and personal goals, best determined through a clinical evaluation.
Retatrutide is an investigational triple agonist still in clinical trials and is not currently FDA-approved or available as a standard treatment, at Groov Wellness or elsewhere.
Groov Wellness pairs medication with personalized dosing, nutrition guidance, and ongoing support to help patients build sustainable results.
How Do Semaglutide, Tirzepatide, And Retatrutide Compare?
Semaglutide, Tirzepatide, and Retatrutide all target appetite and metabolism, but each works differently and carries a different level of clinical evidence.
Semaglutide is an FDA-approved GLP-1 receptor agonist. It mimics a single gut hormone, GLP-1, to slow digestion and reduce hunger signals. In a major clinical trial, adults taking semaglutide 2.4 mg alongside lifestyle intervention lost an average of about 15% of their body weight over 68 weeks. As with any medication, individual results vary based on dosing, adherence, and personal physiology.
Tirzepatide activates both GIP and GLP-1 receptors at once. That dual mechanism has produced average weight loss of around 20% or more in major clinical trials, and for some patients it may result in greater average weight loss than semaglutide alone. That doesn’t make it the automatically better choice for everyone — the right medication depends on medical history, prior response to GLP-1 therapy, tolerability, and individual goals, which is why a clinical evaluation matters more than the numbers alone.
Retatrutide adds a third hormonal target, glucagon, to the GIP/GLP-1 combination used by tirzepatide. Early research suggests this triple-agonist approach could eventually rival or exceed the results seen with semaglutide and tirzepatide, but retatrutide remains investigational, has not received FDA approval, and is not currently available as a standard treatment. San Antonio patients researching next-generation options should treat it as a therapy to watch, not one to expect today.
A quick comparison:
Medication
Mechanism
Average Trial Weight Loss
FDA Status
Semaglutide
GLP-1 agonist
~15% over 68 weeks (major trial)
Approved
Tirzepatide
Dual GIP/GLP-1 agonist
~20% or more (major trials)
Approved
Retatrutide
Triple agonist (GIP/GLP-1/glucagon)
Promising early results, still studied
Investigational, not approved
Clinical trial averages reflect group results, not a guarantee for any individual patient.
Groov Wellness structures its weight loss program around the approved options of semaglutide and tirzepatide, pairing each with dietary guidance. That personalized approach reflects the clinic’s broader mission: helping patients think, feel, and perform their best through plans matched to their biology, not a one-size-fits-all protocol.
How Does Semaglutide Support Weight Loss At Groov Wellness?
Steady results come from consistency, not dramatic swings. Semaglutide is a weekly injection patients administer themselves at home, without a clinic visit required each time. That convenience matters for busy San Antonio adults juggling work, family, and appointments.
The injection process is simple: a small needle under the skin, once a week, on whichever day works best for the patient’s schedule. There’s no rigid protocol dictating a specific day or time.
Dosing isn’t one-size-fits-all, either. At Groov Wellness, a provider evaluates each patient during the initial visit and sets a starting dose based on individual health history and weight loss goals, then adjusts over time to help minimize side effects while building toward a therapeutic dose.
Does Semaglutide Help Reduce Abdominal Fat?
As overall body weight decreases with semaglutide treatment, patients often see reductions in waist circumference and abdominal fat as part of that broader weight loss — the medication doesn’t selectively target fat from one area of the body. That still matters clinically, since visceral fat around the midsection carries greater metabolic risk than fat stored elsewhere.
Supporting Muscle Preservation During Weight Loss
Weight loss achieved with GLP-1 medications like semaglutide can include some reduction in lean muscle mass alongside fat loss. To help preserve muscle during treatment, Groov Wellness providers encourage adequate protein intake, resistance or physical activity when appropriate, and regular follow-up so the plan can be adjusted as needed. Compared to tirzepatide or the investigational retatrutide, semaglutide offers a well-established, predictable option built on years of clinical use rather than early-stage trial data — a track record that carries real weight for San Antonio patients weighing their options.
What Makes Tirzepatide A Strong Option For Some Patients?
Tirzepatide’s dual action — activating both GIP and GLP-1 receptors — is the meaningful clinical difference from semaglutide, which targets GLP-1 alone. That dual mechanism is associated with the higher average weight loss seen in tirzepatide’s trials, and some patients experience it as more consistent appetite control and metabolic support. Tirzepatide also carries FDA approval for type 2 diabetes and obstructive sleep apnea in addition to weight loss, which can matter for San Antonio patients managing more than one metabolic condition. That broader label doesn’t make tirzepatide universally superior; it simply reflects a different, additional evidence base.
Is Tirzepatide Right For You?
Starting tirzepatide follows the same straightforward routine as semaglutide at Groov Wellness: pick one weekly day, take the injection with or without a meal, and let a provider set the dose based on individual response. Whether tirzepatide or semaglutide fits better depends on medical history, prior response to GLP-1 therapy, tolerability, and treatment goals — a clinical evaluation at Groov Wellness helps determine which path fits an individual’s biology, not a generic trend.
Is Retatrutide Available For Weight Loss In San Antonio?
Retatrutide is not currently available for weight loss treatment at Groov Wellness or through standard clinical care anywhere. It remains an investigational triple agonist, still moving through clinical trials, with no confirmed timeline for FDA approval. San Antonio patients curious about triple-hormone-pathway treatment can discuss retatrutide’s progress with Groov Wellness clinicians while focusing on the approved options available today.
Choosing an FDA-approved treatment now doesn’t rule out exploring newer therapies later, once they clear regulatory review. For patients focused on results today, semaglutide and tirzepatide remain the dependable, physician-supervised route forward.
Which Treatment Fits Your San Antonio Weight-Loss Goals?
Personal metabolism, health history, and lifestyle determine the right path more than any single medication name. Semaglutide suits patients seeking a well-established weekly injection paired with dietary coaching. Tirzepatide appeals to those who may benefit from dual-hormone support within the same coordinated plan. Either way, Groov Wellness’s weight loss program pairs medication with dietary guidance and ongoing support, giving San Antonio clients a structured, physician-directed approach rather than a prescription handed over without support.
No two patients start from the same place. That’s why every plan at Groov Wellness begins with lab work and a clinical evaluation, ensuring the medication choice, dosing, and pace match each person’s actual physiology instead of a generic protocol.
Medication alone rarely produces lasting change. Groov Wellness clinicians work alongside each patient to build sustainable habits, addressing nutrition and routine so results extend well beyond the treatment window. Consistency, not just the injection, drives outcomes.
Many San Antonio patients describe reclaiming their energy and confidence once treatment takes hold. That combination of personalized planning and ongoing support makes the decision between therapies feel far less overwhelming.
FAQ
Does Tirzepatide produce better weight-loss results than Semaglutide?
In major clinical trials, tirzepatide’s dual GIP/GLP-1 action has produced average weight loss of 20% or more, compared with an average of about 15% for semaglutide over 68 weeks. These are group averages, not guaranteed outcomes for any one patient — actual results depend on dosing, adherence, and individual physiology, which is why a clinical evaluation matters more than the numbers alone.
Can patients get Retatrutide for weight loss at Groov Wellness?
No. Retatrutide remains investigational and has not received FDA approval, so it isn’t currently available at Groov Wellness or through standard clinical care. Groov Wellness structures its San Antonio weight loss program around the two FDA-approved options, semaglutide and tirzepatide.
How often do patients inject Semaglutide?
Semaglutide is a self-injectable weekly treatment that patients administer at home using a small needle under the skin, choosing whichever day best fits their schedule.
Does Semaglutide guarantee a specific amount of weight loss?
No. Clinical trial averages, such as the roughly 15% body weight reduction seen over 68 weeks in a major semaglutide trial, reflect group results rather than a guarantee for any one patient. Actual results depend on dosing, adherence, and individual physiology, which is why Groov Wellness bases each plan on a clinical evaluation rather than a fixed expectation.
Conclusion
Semaglutide and tirzepatide remain the two FDA-approved, physician-supervised options for medical weight loss at Groov Wellness, while retatrutide continues to advance through clinical trials as a promising but investigational therapy. The right choice between semaglutide and tirzepatide depends on your health history, tolerability, prior response, and personal goals — factors best evaluated through lab work and a clinical assessment rather than a one-size-fits-all recommendation. If you’re a San Antonio adult considering semaglutide or tirzepatide, schedule a clinical evaluation with Groov Wellness to find the option that fits your physiology and supports sustainable, long-term results.
